Coagulopathy, anticoagulant treatment in COVID-19 and thrombosis postvaccine

Abstract

Coagulopathy and thrombosis are serious situations that COVID-19 patients require hospitalization. In these patients, procoa-gulant and fibrinolytic mechanisms are altered that condition a progressive and severe procoagulant state. Timely anticoagu-lation in these patients is important, but questions have been raised about the type, dose, and timing of anticoagulation. The guidelines and consensus documents offer general suggestions on the dose of LMWH based on the severity of the disease and the risk of thrombosis, but a relationship between coagulation markers and anticoagulation regimen is still lacking. Many clinical trials are underway that address these issues; Participation in these trials to determine the best treatment strategies for COVID-19 patients is encouraged. Increasing knowledge with rapid exchange is necessary to adequately care for patients in this pandemic.